U.S. FDA approves Gilead's COVID-19 drug for young children
Send a link to a friend
 [April 26, 2022]
(Reuters) -The U.S. drug regulator
on Monday granted the first full approval for treating COVID-19 in
children aged 28 days and older to Gilead Sciences Inc's drug remdesivir.
The move comes months after the agency expanded the drug's emergency use
authorization to also include children below 12 years of age weighing at
least 3.5 kilograms.
[to top of second column]
|
 The Food and Drug Administration's
(FDA) decision makes the drug the first approved COVID-19 treatment
for children less than 12 years of age, the agency said.
The approval is applicable to children who are hospitalized, or have
mild-to-moderate disease and are at high risk of severe COVID-19.
(Reporting by Manas Mishra in Bengaluru; Editing by Aditya Soni)
[© 2022 Thomson Reuters. All rights
reserved.] This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
